pharmaphorum17m
Italian decision sets up launch of Oncopeptides' Pepaxti
The publication of the pricing and reimbursement decision for Pepaxti (melflufen) in the Gazetta Ufficiale removes the last ...
pharmaphorum59m
New UK biotech Swarm lands with T-cell therapy mission
Swarm was formed in 2022 and has now emerged with Martin Olin – previously chief executive of BerGenBio and Symphogen – at ...